KYORIN Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
KYORIN Pharmaceutical's earnings have been declining at an average annual rate of -8%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 0.6% per year. KYORIN Pharmaceutical's return on equity is 3.4%, and it has net margins of 3.6%.
Key information
-8.0%
Earnings growth rate
-6.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 0.6% |
| Return on equity | 3.4% |
| Net Margin | 3.6% |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How KYORIN Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 119,830 | 4,260 | 35,636 | 10,903 |
| 30 Sep 23 | 119,114 | 5,238 | 35,807 | 10,903 |
| 30 Jun 23 | 116,505 | 4,216 | 35,112 | 10,903 |
| 31 Mar 23 | 113,270 | 4,723 | 34,140 | 10,903 |
| 31 Dec 22 | 108,524 | 5,826 | 34,575 | 8,897 |
| 30 Sep 22 | 105,525 | 5,053 | 33,931 | 8,897 |
| 30 Jun 22 | 105,458 | 5,577 | 34,316 | 8,897 |
| 31 Mar 22 | 105,534 | 3,932 | 35,536 | 8,897 |
| 31 Dec 21 | 105,666 | 4,109 | 34,767 | 9,703 |
| 30 Sep 21 | 104,271 | 4,133 | 35,256 | 9,703 |
| 30 Jun 21 | 102,910 | 4,059 | 36,827 | 9,703 |
| 31 Mar 21 | 102,904 | 6,130 | 36,138 | 9,703 |
| 31 Dec 20 | 106,324 | 6,279 | 37,384 | 10,987 |
| 30 Sep 20 | 109,419 | 7,433 | 38,096 | 10,987 |
| 30 Jun 20 | 108,923 | 6,478 | 37,870 | 10,987 |
| 31 Mar 20 | 109,983 | 6,149 | 38,541 | 10,987 |
| 31 Dec 19 | 110,217 | 6,131 | 37,430 | 10,790 |
| 30 Sep 19 | 111,559 | 5,486 | 37,662 | 10,790 |
| 30 Jun 19 | 114,238 | 7,072 | 37,559 | 10,790 |
| 31 Mar 19 | 113,620 | 6,869 | 37,646 | 10,790 |
| 31 Dec 18 | 109,734 | 5,567 | 35,873 | 14,243 |
| 30 Sep 18 | 110,242 | 7,551 | 36,073 | 14,243 |
| 30 Jun 18 | 109,313 | 5,258 | 38,383 | 14,243 |
| 31 Mar 18 | 110,640 | 6,574 | 38,510 | 14,243 |
| 31 Dec 17 | 111,460 | 8,701 | 37,987 | 13,569 |
| 30 Sep 17 | 111,503 | 5,861 | 39,596 | 13,569 |
| 30 Jun 17 | 114,124 | 7,118 | 39,692 | 13,569 |
| 31 Mar 17 | 115,373 | 7,305 | 40,544 | 13,569 |
| 31 Dec 16 | 116,850 | 7,531 | 41,082 | 13,019 |
| 30 Sep 16 | 121,725 | 13,356 | 39,875 | 13,019 |
| 30 Jun 16 | 120,623 | 14,462 | 38,802 | 13,019 |
| 31 Mar 16 | 119,483 | 13,639 | 39,467 | 13,019 |
| 31 Dec 15 | 118,988 | 13,324 | 39,731 | 13,514 |
| 30 Sep 15 | 114,395 | 11,536 | 39,814 | 13,514 |
| 30 Jun 15 | 113,291 | 11,140 | 39,795 | 13,514 |
| 31 Mar 15 | 113,121 | 12,064 | 38,271 | 13,514 |
| 31 Dec 14 | 111,572 | 12,324 | 39,388 | 11,359 |
| 30 Sep 14 | 111,661 | 11,123 | 39,027 | 11,359 |
| 30 Jun 14 | 111,558 | 11,710 | 39,127 | 11,359 |
| 31 Mar 14 | 111,400 | 12,025 | 39,385 | 11,359 |
| 31 Dec 13 | 111,232 | 12,432 | 40,105 | 11,059 |
| 30 Sep 13 | 109,928 | 12,524 | 39,840 | 11,059 |
| 30 Jun 13 | 107,848 | 12,580 | 38,344 | 11,059 |
Quality Earnings: 4569 has high quality earnings.
Growing Profit Margin: 4569's current net profit margins (3.6%) are lower than last year (5.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4569's earnings have declined by 8% per year over the past 5 years.
Accelerating Growth: 4569's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4569 had negative earnings growth (-26.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (0.6%).
Return on Equity
High ROE: 4569's Return on Equity (3.4%) is considered low.